Clinuvel Pharmaceuticals Valuation Multiples

Clinuvel Pharmaceuticals Overview

About Clinuvel Pharmaceuticals

Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient’s quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel’s earnings stem from Europe and the US.

Founded

1999

HQ

Employees

16

Website

clinuvel.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $70M

EBITDA: $30M

EV

$164M

Valuation Multiples

Multiples.vc

Start free trial

Clinuvel Pharmaceuticals Financials

Clinuvel Pharmaceuticals reported last 12-month revenue of $70M and EBITDA of $30M.

In the same LTM period, Clinuvel Pharmaceuticals generated $66M in gross profit, $30M in EBITDA, and $26M in net income.

Clinuvel Pharmaceuticals P&L

In the most recent fiscal year, Clinuvel Pharmaceuticals reported revenue of $68M and EBITDA of $41M.

Clinuvel Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

Clinuvel Pharmaceuticals Stock Performance

Clinuvel Pharmaceuticals has current market cap of $330M, and enterprise value of $164M.

Clinuvel Pharmaceuticals' stock price is $6.55.

Clinuvel Pharmaceuticals Valuation Multiples

Clinuvel Pharmaceuticals trades at 2.4x EV/Revenue multiple, and 5.5x EV/EBITDA.

Clinuvel Pharmaceuticals Financial Valuation Multiples

As of April 19, 2026, Clinuvel Pharmaceuticals has market cap of $330M and EV of $164M.

Equity research analysts estimate Clinuvel Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Clinuvel Pharmaceuticals has a P/E ratio of 12.8x.

Clinuvel Pharmaceuticals Margins & Growth Rates

Clinuvel Pharmaceuticals' revenue in the last 12 month grew by 8%.

Clinuvel Pharmaceuticals' revenue per employee in the last FY averaged $4.3M, while opex per employee averaged $1.5M for the same period.

Clinuvel Pharmaceuticals' rule of 40 is 48% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Clinuvel Pharmaceuticals' rule of X is 57% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Clinuvel Pharmaceuticals Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Clinuvel Pharmaceuticals M&A Activity

Clinuvel Pharmaceuticals acquired XXX companies to date.

Last acquisition by Clinuvel Pharmaceuticals was on XXXXXXXX, XXXXX. Clinuvel Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Clinuvel Pharmaceuticals Investment Activity

Clinuvel Pharmaceuticals invested in XXX companies to date.

Clinuvel Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Clinuvel Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).